Concepedia

The role of second-line chemotherapy in small cell lung cancer: a retrospective analysis

Paul Zarogoulidis, Efimia Boutsikou, Kaid Darwiche, Lutz Freitag, Dionysios Spyratos, Qiang Li, Wolfgang Hohenforst‐Schmidt, Maria Kipourou, Kontakiotis Theodoros, Κonstantinos Porpodis,

OncoTargets and Therapy · 2013 · 11 citations · 22 references

DOIFull text

Open access

Abstract

Continuation with carboplatin/paclitaxel or carboplatin/etoposide as second-line chemotherapy has no significant survival impact, and it did not improve response rates.

References

22

Topotecan Versus Cyclophosphamide, Doxorubicin, and Vincristine for the Treatment of Recurrent Small-Cell Lung Cancer

Joachim von Pawel, Joan H. Schiller, Frances A. Shepherd et al. · Journal of Clinical Oncology · 1999 · 943 citations

Randomized study of cyclophosphamide, doxorubicin, and vincristine versus etoposide and cisplatin versus alternation of these two regimens in extensive small-cell lung cancer: a phase III trial of the Southeastern Cancer Study Group.

Bruce J. Roth, David H. Johnson, Lawrence H. Einhorn et al. · Journal of Clinical Oncology · 1992 · 548 citations

Randomized Trial of Cyclophosphamide, Doxorubicin, and Vincristine Versus Cisplatin and Etoposide Versus Alternation of These Regimens in Small-Cell Lung Cancer

M. Fukuoka, Kiyoyuki Furuse, Nagahiro Saijo et al. · JNCI Journal of the National Cancer Institute · 1991 · 456 citations

, , +17

Phase III Study of Oral Compared With Intravenous Topotecan As Second-Line Therapy in Small-Cell Lung Cancer

John R. Eckardt, Joachim von Pawel, Jean-Louis Pujol et al. · Journal of Clinical Oncology · 2007 · 380 citations

Randomized comparison of etoposide-cisplatin vs. etoposide-carboplatin and irradiation in small-cell lung cancer

D. Skarlos, E. Samantas, P. Kosmidis et al. · Annals of Oncology · 1994 · 274 citations · Full text

, , +8